Get informed when a big investor buys or sells
+ Follow-4.79%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 688505.SS is -4.79%. That is below the sector sector average of 11.3%. Investors often review this figure alongside Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 688505.SS currently prints -4.79% for ROE, while the sector average sits near 11.3%. That is roughly 142.4% below the sector mean. Large gaps often invite a closer look at Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. converts resources into returns. At -4.79%, 688505.SS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 688505.SS's ROE (-4.79%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.